The presentation of positive Phase 2 data typically generates optimism among investors, as it indicates progress in the drug development pipeline and potential for future revenue growth. The significant reductions in APOC3 and triglycerides are particularly promising for the treatment of hypertriglyceridemia and mixed dyslipidemia, which may lead to increased investor confidence and a potential rise in stock price.